173 related articles for article (PubMed ID: 38915460)
1. PDE4 inhibitors: potential protective effects in inflammation and vascular diseases.
Fan T; Wang W; Wang Y; Zeng M; Liu Y; Zhu S; Yang L
Front Pharmacol; 2024; 15():1407871. PubMed ID: 38915460
[TBL] [Abstract][Full Text] [Related]
2. Phosphodiesterase-4 Inhibitors for the Treatment of Inflammatory Diseases.
Li H; Zuo J; Tang W
Front Pharmacol; 2018; 9():1048. PubMed ID: 30386231
[TBL] [Abstract][Full Text] [Related]
3. Phosphodiesterase-4 Inhibition in the Management of Psoriasis.
Crowley EL; Gooderham MJ
Pharmaceutics; 2023 Dec; 16(1):. PubMed ID: 38258034
[TBL] [Abstract][Full Text] [Related]
4. The preclinical pharmacology of roflumilast--a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary disease.
Hatzelmann A; Morcillo EJ; Lungarella G; Adnot S; Sanjar S; Beume R; Schudt C; Tenor H
Pulm Pharmacol Ther; 2010 Aug; 23(4):235-56. PubMed ID: 20381629
[TBL] [Abstract][Full Text] [Related]
5. An Overview of PDE4 Inhibitors in Clinical Trials: 2010 to Early 2022.
Crocetti L; Floresta G; Cilibrizzi A; Giovannoni MP
Molecules; 2022 Aug; 27(15):. PubMed ID: 35956914
[TBL] [Abstract][Full Text] [Related]
6. Phosphodiesterase 4 inhibition in the treatment of psoriasis, psoriatic arthritis and other chronic inflammatory diseases.
Wittmann M; Helliwell PS
Dermatol Ther (Heidelb); 2013 Jun; 3(1):1-15. PubMed ID: 23888251
[TBL] [Abstract][Full Text] [Related]
7. Phosphodiesterase-4 enzyme as a therapeutic target in neurological disorders.
Bhat A; Ray B; Mahalakshmi AM; Tuladhar S; Nandakumar DN; Srinivasan M; Essa MM; Chidambaram SB; Guillemin GJ; Sakharkar MK
Pharmacol Res; 2020 Oct; 160():105078. PubMed ID: 32673703
[TBL] [Abstract][Full Text] [Related]
8. Phosphodiesterase 4 inhibitors in diabetic nephropathy.
Ookawara M; Nio Y
Cell Signal; 2022 Feb; 90():110185. PubMed ID: 34785349
[TBL] [Abstract][Full Text] [Related]
9. Phosphodiesterase 4 Inhibitors in Immune-mediated Diseases: Mode of Action, Clinical Applications, Current and Future Perspectives.
Sakkas LI; Mavropoulos A; Bogdanos DP
Curr Med Chem; 2017; 24(28):3054-3067. PubMed ID: 28554321
[TBL] [Abstract][Full Text] [Related]
10. [Progress in PDE4 targeted therapy for inflammatory diseases].
Song SD; Tang HF
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 May; 43(3):353-8. PubMed ID: 24998661
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological Profile of Difamilast, a Novel Selective Phosphodiesterase 4 Inhibitor, for Topical Treatment of Atopic Dermatitis.
Hiyama H; Arichika N; Okada M; Koyama N; Tahara T; Haruta J
J Pharmacol Exp Ther; 2023 Jul; 386(1):45-55. PubMed ID: 37041087
[TBL] [Abstract][Full Text] [Related]
12. Crisaborole: Phosphodiesterase inhibitor for treatment of atopic dermatitis.
Paton DM
Drugs Today (Barc); 2017 Apr; 53(4):239-245. PubMed ID: 28492291
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Chong J; Leung B; Poole P
Cochrane Database Syst Rev; 2017 Sep; 9(9):CD002309. PubMed ID: 28922692
[TBL] [Abstract][Full Text] [Related]
14. ME3183, a novel phosphodiesterase-4 inhibitor, exhibits potent anti-inflammatory effects and is well tolerated in a non-clinical study.
Kubota-Ishida N; Kaji C; Matsumoto S; Wakabayashi T; Matsuhira T; Okura I; Cho N; Isshiki S; Kumura K; Tabata Y
Eur J Pharmacol; 2024 Jan; 962():176202. PubMed ID: 37996010
[TBL] [Abstract][Full Text] [Related]
15. Crisaborole Topical Ointment, 2%: A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis.
Jarnagin K; Chanda S; Coronado D; Ciaravino V; Zane LT; Guttman-Yassky E; Lebwohl MG
J Drugs Dermatol; 2016 Apr; 15(4):390-6. PubMed ID: 27050693
[TBL] [Abstract][Full Text] [Related]
16. Phosphodiesterase inhibitors in the treatment of inflammatory diseases.
Page CP; Spina D
Handb Exp Pharmacol; 2011; (204):391-414. PubMed ID: 21695650
[TBL] [Abstract][Full Text] [Related]
17. Can Phosphodiesterase 4 Inhibitor Therapy Be Used in Respiratory Diseases Other Than Chronic Obstructive Pulmonary Disease?
Goonathilake MR; Waqar S; George S; Jean-Baptiste W; Yusuf Ali A; Inyang B; Koshy FS; George K; Poudel P; Chalasani R; Mohammed L
Cureus; 2022 Jul; 14(7):e27132. PubMed ID: 36017299
[TBL] [Abstract][Full Text] [Related]
18. Phosphodiesterase 4 and its inhibitors in inflammatory diseases.
Jin SL; Ding SL; Lin SC
Chang Gung Med J; 2012; 35(3):197-210. PubMed ID: 22735051
[TBL] [Abstract][Full Text] [Related]
19. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease.
Chong J; Leung B; Poole P
Cochrane Database Syst Rev; 2013 Nov; (11):CD002309. PubMed ID: 24190161
[TBL] [Abstract][Full Text] [Related]
20. Crisaborole efficacy in murine models of skin inflammation and Staphylococcus aureus infection.
Youn C; Dikeman DA; Chang E; Liu H; Nolan SJ; Alphonse MP; Joyce DP; Liu Q; Meixiong J; Dong X; Miller LS; Archer NK
Exp Dermatol; 2023 Apr; 32(4):425-435. PubMed ID: 36461082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]